The Company is a Korea-based company principally engaged in the research and development of biological pharmaceuticals. The Company researches and develops sepsis therapeutics, LPS removal kits, immune anticancer drugs, vaccine adjuvants, highly pathogenic influenza therapeutics and hangover recovery drugs. The Company was established on April 25, 2016. The company shares are listed on KONEX Exchange on April 24, 2020.
Headquarters
666Th Floor, Achasan-Ro, Seongdong-Gu
Seoul; Seoul;
Contact Details: Purchase the Dandi Bioscience Inc. report to view the information.
Website: http://www.dandibio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service